OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY

Victoria P. Werth(Philadelphia VA Medical Center), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Peter E. Lipsky(Ampel BioSolutions (United States)), Joan T. Merrill(Oklahoma Medical Research Foundation), Shimon Korish(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Z. Liu(Bristol-Myers Squibb (United States)), Thomas Dörner(German Rheumatism Research Centre), Shijie Tang(Shantou University), Peter Schäfer(Bristol-Myers Squibb (United States)), Ronald van Vollenhoven(Amsterdam University Medical Centers), Martin Stern(Bristol-Myers Squibb (United States)), Michael Weiswasser(Bristol-Myers Squibb (United States))
Annals of the Rheumatic Diseases
May 25, 2021
10.1136/annrheumdis-2021-eular.2181
Cited by 8

Related Papers

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
|Nature|2014|1k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k